G
Gerjo J. de Knegt
Researcher at Erasmus University Rotterdam
Publications - 21
Citations - 656
Gerjo J. de Knegt is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 12, co-authored 21 publications receiving 565 citations. Previous affiliations of Gerjo J. de Knegt include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis
Jurriaan E. M. de Steenwinkel,Gerjo J. de Knegt,Marian T. ten Kate,Alex van Belkum,Henri A. Verbrugh,Kristin Kremer,Dick van Soolingen,Irma A. J. M. Bakker-Woudenberg +7 more
TL;DR: Optimization of dosage of anti-TB drugs is required to achieve maximum drug concentrations at the site of infection in order to maximize reduction in Mtb load and to minimize the emergence and selection of resistance.
Journal ArticleDOI
Drug susceptibility of mycobacterium tuberculosis Beijing genotype and association with MDR TB
Jurriaan E. M. de Steenwinkel,Marian T. ten Kate,Gerjo J. de Knegt,Kristin Kremer,Rob E. Aarnoutse,Martin J. Boeree,Henri A. Verbrugh,Dick van Soolingen,Irma A. J. M. Bakker-Woudenberg +8 more
TL;DR: The activity of antituberculosis drugs against susceptible Beijing and East-African/Indian genotype M. tuberculosis strains showed high rates of mutation within a wide range of drug concentrations, possibly explaining this genotype’s association with multidrug-resistant tuberculosis.
Journal ArticleDOI
Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model
Jurriaan E. M. de Steenwinkel,Rob E. Aarnoutse,Gerjo J. de Knegt,Marian T. ten Kate,Marga Teulen,Henri A. Verbrugh,Martin J. Boeree,Dick van Soolingen,Irma A. J. M. Bakker-Woudenberg +8 more
TL;DR: The findings indicate that the currently used rifampin dosage in the therapy of TB is too low, and a rifampsin dosage of 80 mg/kg/d enabled a significant reduction in therapy duration without adverse effects.
Journal ArticleDOI
Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis.
Gerjo J. de Knegt,Oskar Bruning,Marian T. ten Kate,Mark de Jong,Alex van Belkum,Alex van Belkum,Hubert P. Endtz,Timo M. Breit,Irma A. J. M. Bakker-Woudenberg,Jurriaan E. M. de Steenwinkel +9 more
TL;DR: In this paper, the authors performed a genome-wide transcriptional profile analysis for Mycobacterium tuberculosis (M. tuberculosis) using microarray technology and qRT-PCR analysis.
Journal ArticleDOI
The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box
Lindsey H.M. te Brake,Gerjo J. de Knegt,Jurriaan E. M. de Steenwinkel,Teunis J. P. van Dam,David M. Burger,Frans G. M. Russel,Reinout van Crevel,Jan B. Koenderink,Rob E. Aarnoutse +8 more
TL;DR: The role of efflux transporters in TB drug disposition is reviewed and the promise ofefflux pump inhibition from a novel holistic perspective is evaluated.